1. AB0496 Tumor necrosis factor (TNF)-inhibitor dose escalation in rheumatoid arthritis (RA) patients in a united states (US) pharmacy benefits management (PBM) setting. (23rd January 2014) Authors: Blume, S.W.; Fox, K.M.; Joseph, G.; Chuang, C.-C.; Thomas, J.; Gandra, S.R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0499 Post-discontinuation treatment patterns for tumor necrosis factor-blockers in rheumatoid arthritis patients in the US. (23rd January 2014) Authors: Schabert, V.F.; Fox, K.M.; Watson, C.; Yeaw, J.; Goodman, S.; Gandra, S.R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients. (23rd January 2014) Authors: Fisher, M.; Watson, C.; Fox, K.M.; Chen, Y.-W.; Gandra, S.R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗